UnitedHealth, FTC Reach Proposed Settlement in Insulin Case

Why It Matters

The settlement could curb anti‑competitive practices that have driven up insulin costs, offering relief to patients and setting a precedent for tighter oversight of pharmacy‑benefit managers.

Key Takeaways

• FTC pauses case against Optum Rx and Emisar pending settlement
• Optum Rx joins CVS and Express Scripts in PBM insulin settlement talks
• Settlement would resolve all FTC claims against UnitedHealth’s PBM group
• PBMs control about 80% of U.S. prescriptions, influencing insulin prices
• Deal details undisclosed, but could reshape pharmacy‑benefit manager practices

Pulse Analysis

The Federal Trade Commission’s lawsuit against the nation’s three dominant pharmacy‑benefit managers (PBMs) has centered on allegations that they manipulate insulin pricing to capture higher rebates. By steering patients toward higher‑list‑price drugs, PBMs can inflate out‑of‑pocket costs despite negotiating discounts with manufacturers. This practice has drawn scrutiny from lawmakers and consumer advocates, especially as insulin remains a life‑saving medication with limited alternatives. The FTC’s action reflects a broader regulatory push to increase transparency in drug pricing and to dismantle structures that enable price inflation.

In early 2024, Express Scripts became the first of the “Big Three” to settle, agreeing to delink its compensation from the rebates it secures and to stop favoring high‑list‑price drugs. CVS Caremark followed with a proposed settlement, while Cigna’s Express Scripts had already resolved its case. UnitedHealth’s Optum Rx now appears poised to join them, with the FTC pausing its case pending a consent agreement. Although the terms remain confidential, the pattern suggests the FTC is demanding structural changes—such as greater price transparency and the removal of rebate‑driven incentives—that could reshape PBM business models across the industry.

For patients, these settlements promise potential reductions in insulin out‑of‑pocket expenses and greater predictability in drug costs. For the broader healthcare market, they signal a shift toward heightened oversight of PBMs, which could spur competition and encourage alternative pricing models, like value‑based contracts. Industry observers anticipate that the FTC’s approach may extend to other therapeutic areas, prompting PBMs to reevaluate their rebate structures and possibly accelerating legislative efforts aimed at capping insulin prices nationwide.